234 related articles for article (PubMed ID: 33621416)
41. Drug-mediated targeted disruption of multiple protein activities through functional inhibition of the Hsp90 chaperone complex.
Stravopodis DJ; Margaritis LH; Voutsinas GE
Curr Med Chem; 2007; 14(29):3122-38. PubMed ID: 18220746
[TBL] [Abstract][Full Text] [Related]
42. The Right Tool for the Job: An Overview of Hsp90 Inhibitors.
Koren J; Blagg BSJ
Adv Exp Med Biol; 2020; 1243():135-146. PubMed ID: 32297216
[TBL] [Abstract][Full Text] [Related]
43. Conformational dynamics of the molecular chaperone Hsp90 in complexes with a co-chaperone and anticancer drugs.
Phillips JJ; Yao ZP; Zhang W; McLaughlin S; Laue ED; Robinson CV; Jackson SE
J Mol Biol; 2007 Oct; 372(5):1189-203. PubMed ID: 17764690
[TBL] [Abstract][Full Text] [Related]
44. HSP90 and its inhibitors.
Hao H; Naomoto Y; Bao X; Watanabe N; Sakurama K; Noma K; Motoki T; Tomono Y; Fukazawa T; Shirakawa Y; Yamatsuji T; Matsuoka J; Takaoka M
Oncol Rep; 2010 Jun; 23(6):1483-92. PubMed ID: 20428801
[TBL] [Abstract][Full Text] [Related]
45. Molecular imaging of the efficacy of heat shock protein 90 inhibitors in living subjects.
Chan CT; Paulmurugan R; Gheysens OS; Kim J; Chiosis G; Gambhir SS
Cancer Res; 2008 Jan; 68(1):216-26. PubMed ID: 18172314
[TBL] [Abstract][Full Text] [Related]
46. Inhibiting protein-protein interactions of Hsp90 as a novel approach for targeting cancer.
Dutta Gupta S; Bommaka MK; Banerjee A
Eur J Med Chem; 2019 Sep; 178():48-63. PubMed ID: 31176095
[TBL] [Abstract][Full Text] [Related]
47. Prospective identification of resistance mechanisms to HSP90 inhibition in KRAS mutant cancer cells.
Rouhi A; Miller C; Grasedieck S; Reinhart S; Stolze B; Döhner H; Kuchenbauer F; Bullinger L; Fröhling S; Scholl C
Oncotarget; 2017 Jan; 8(5):7678-7690. PubMed ID: 28032595
[TBL] [Abstract][Full Text] [Related]
48. Recent advances toward the development of Hsp90 C-terminal inhibitors.
Amatya E; Blagg BSJ
Bioorg Med Chem Lett; 2023 Jan; 80():129111. PubMed ID: 36549397
[TBL] [Abstract][Full Text] [Related]
49. The therapeutic target Hsp90 and cancer hallmarks.
Miyata Y; Nakamoto H; Neckers L
Curr Pharm Des; 2013; 19(3):347-65. PubMed ID: 22920906
[TBL] [Abstract][Full Text] [Related]
50. To fold or not to fold: modulation and consequences of Hsp90 inhibition.
Peterson LB; Blagg BS
Future Med Chem; 2009 May; 1(2):267-83. PubMed ID: 20161407
[TBL] [Abstract][Full Text] [Related]
51. Differential expression of heat shock protein 90 isoforms in small cell lung cancer.
Lee JH; Kang KW; Kim JE; Hwang SW; Park JH; Kim SH; Ji JH; Kim TG; Nam HY; Roh MS; Lee EH; Park MI; Kim MS; Lee HW
Int J Clin Exp Pathol; 2015; 8(8):9487-93. PubMed ID: 26464709
[TBL] [Abstract][Full Text] [Related]
52. Heat shock protein 90: the cancer chaperone.
Neckers L
J Biosci; 2007 Apr; 32(3):517-30. PubMed ID: 17536171
[TBL] [Abstract][Full Text] [Related]
53. Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers.
Jhaveri K; Taldone T; Modi S; Chiosis G
Biochim Biophys Acta; 2012 Mar; 1823(3):742-55. PubMed ID: 22062686
[TBL] [Abstract][Full Text] [Related]
54. Update on Hsp90 inhibitors in clinical trial.
Kim YS; Alarcon SV; Lee S; Lee MJ; Giaccone G; Neckers L; Trepel JB
Curr Top Med Chem; 2009; 9(15):1479-92. PubMed ID: 19860730
[TBL] [Abstract][Full Text] [Related]
55. Hsp90 isoforms: functions, expression and clinical importance.
Sreedhar AS; Kalmár E; Csermely P; Shen YF
FEBS Lett; 2004 Mar; 562(1-3):11-5. PubMed ID: 15069952
[TBL] [Abstract][Full Text] [Related]
56. Middle domain of human Hsp90 isoforms differentially binds Aha1 in human cells and alters Hsp90 activity in yeast.
Synoradzki K; Bieganowski P
Biochim Biophys Acta; 2015 Feb; 1853(2):445-52. PubMed ID: 25486457
[TBL] [Abstract][Full Text] [Related]
57. Recent update on discovery and development of Hsp90 inhibitors as senolytic agents.
Dutta Gupta S; Pan CH
Int J Biol Macromol; 2020 Oct; 161():1086-1098. PubMed ID: 32561284
[TBL] [Abstract][Full Text] [Related]
58. Heat Shock Protein 90 Inhibition in Cancer Drug Discovery: From Chemistry to Futural Clinical Applications.
Özgür A; Tutar Y
Anticancer Agents Med Chem; 2016; 16(3):280-90. PubMed ID: 26295332
[TBL] [Abstract][Full Text] [Related]
59. Hsp90 inhibitors as anti-cancer agents, from basic discoveries to clinical development.
Soga S; Akinaga S; Shiotsu Y
Curr Pharm Des; 2013; 19(3):366-76. PubMed ID: 22920907
[TBL] [Abstract][Full Text] [Related]
60. HSP90alpha and HSP90beta isoforms selectively modulate MHC class II antigen presentation in B cells.
Houlihan JL; Metzler JJ; Blum JS
J Immunol; 2009 Jun; 182(12):7451-8. PubMed ID: 19494268
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
